Renaissance Capital logo

bluebird bio Priced, Nasdaq: BLUE

Developing gene therapies for severe genetic and orphan diseases.

Industry: Health Care

First Day Return: +58.3%

Industry: Health Care

Developing gene therapies for severe genetic and orphan diseases.
more less

bluebird bio (BLUE) Performance